GC Biopharma

GC Biopharma Forward P/E

The Forward P/E Ratio of GC Biopharma (006280.KS) as of Nov 4, 2026 is -425.63. In the previous year, Forward P/E Ratio was -75.70 — a change of 462.28% (lower).

Forward P/E

-425.63

YoY

462.28%

Last updated:

Forward P/E Ratio of GC Biopharma is 2025 -425.63 . Forward P/E Ratio of GC Biopharma was 2024 -75.70 . It decreases by 462.28% lower compared to the previous year.

The GC Biopharma Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
57.78 KRW
Jan 1, 2019
-546.88 KRW
Jan 1, 2020
24.54 KRW
Jan 1, 2021
16.15 KRW
Jan 1, 2022
30.39 KRW
Jan 1, 2023
-74.70 KRW
Jan 1, 2024
-75.70 KRW
Jan 1, 2025
-425.63 KRW
The GC Biopharma Forward P/E history
YEARForward P/EYoY
-425.63+462.28%
-75.70+1.34%
-74.70-345.77%
30.39+88.24%
16.15-34.22%
24.54-104.49%
-546.88-1,046.50%
57.78+54.65%
37.36+18.26%
31.59+50.81%
20.95-11.61%
23.70—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GC Biopharma Stock analysis

What does GC Biopharma do? GC Biopharma Corp generates revenue through the production and sale of pharmaceutical products such as blood products, general products, vaccines, over-the-counter drugs, diagnostic reagents, placental injections, cell therapies, and blood diagnostic products. The company also offers genome analysis services. Its primary customers include healthcare providers and institutions requiring pharmaceuticals and diagnostic solutions. The firm targets segments focused on biopharmaceutical manufacturing and genomic healthcare services. Green Cross Corp, the parent company, operates under the same business model, emphasizing pharmaceutical manufacturing and genomic services. The company's product portfolio spans blood-related treatments, vaccines, and advanced diagnostic tools, catering to both general medical needs and specialized healthcare applications. Revenue streams are derived from direct sales of these products and services to healthcare sectors. The business model integrates the production of traditional pharmaceuticals with innovative genomic services, creating a diversified revenue base. Key segments include blood product manufacturing, vaccine development, and diagnostic reagent sales, alongside cell therapy and placental injection offerings. Customers are primarily healthcare institutions and providers seeking comprehensive pharmaceutical and diagnostic solutions. GC Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GC Biopharma stock

Forward P/E Ratio of GC Biopharma is -425.63 in 2025.

Forward P/E Ratio of GC Biopharma changed from -75.70 to -425.63, representing a 462.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio GC Biopharma since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's GC Biopharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — GC Biopharma

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — GC Biopharma